SCHEDULE: Kynam Capital Discloses 5.54% Stake in Cogent Biosciences

Kynam Capital Management, LP, along with its GP and Yue Tang, has disclosed a beneficial ownership of 5.54% in Cogent Biosciences, Inc. common stock.

Summary

• Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang collectively beneficially own 7,886,172 shares of Cogent Biosciences, Inc. Common Stock.
• This ownership represents 5.54% of the class of securities.
• The reporting persons share both voting and dispositive power over all 7,886,172 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The filing is an Amendment No. 1 to a previous Schedule 13G statement.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. It simply reports a significant institutional stake.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Cogent Biosciences, a company operating in the biotechnology sector. Such disclosures are common as investment firms adjust their portfolios and reach reporting thresholds, reflecting their confidence or strategic positioning within specific companies or the broader industry.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor may influence market perception and trading activity, potentially signaling institutional confidence in the company.

Key Dates

Keywords

Cogent Biosciences, Kynam Capital Management, Yue Tang, Beneficial Ownership, Institutional Investment, Common Stock, SEC Filing, Schedule 13G, Biotechnology